Rationale for one stage exchange of infected hip replacement using uncemented implants and antibiotic impregnated bone graft by Winkler, Heinz





I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   M Me ed di ic ca al l   S Sc ci ie en nc ce es s   
2009; 6(5):247-252 
© Ivyspring International Publisher. All rights reserved 
Review 
Rationale for one stage exchange of infected hip replacement using 
uncemented implants and antibiotic impregnated bone graft 
Heinz Winkler 
 
Osteitis Centre, Privatklinik Döbling, HeiligenstaedterStrasse 57-63, A-1190 Vienna, AUSTRIA   

 Correspondence to: Heinz Winkler, Tel.: +43 136066 8000; Fax: +43 271920187; E-mail: h-winkler@aon.at. 
http://www.osteomyelitis.at 
Received: 2009.08.03; Accepted: 2009.09.04; Published: 2009.09.04 
Abstract 
Infection of a total hip replacement (THR) is considered a devastating complication, necessitating 
its complete removal and thorough debridement of the site. It is undoubted that one stage ex-
change, if successful, would provide the best benefit both for the patient and the society. Still the 
fear of re-infection dominates the surgeons´ decisions and in the majority of cases directs them to 
multiple stage protocols. However, there is no scientifically based argument for that practice. 
Successful eradication of infection with two stage procedures is reported to average 80% to 98%. 
On the other hand a literature review of Jackson and Schmalzried (CORR 2000) summarizing the 
results of 1,299 infected hip replacements treated with direct exchange (almost exclusively using 
antibiotic loaded cement), reports of 1,077 (83%) having been successful. The comparable results 
suggest, that the major factor for a successful outcome with traditional approaches may be found 
in the quality of surgical debridement and dead space management. Failures in all protocols seem to 
be caused by small fragments of bacterial colonies remaining after debridement, whereas neither 
systemic antibiotics nor antibiotic loaded bone cement (PMMA) have been able to improve the 
situation significantly.  
Reasons for failure may be found in the limited sensitivity of traditional bacterial culturing and 
reduced antibiotic susceptibility of involved pathogens, especially considering biofilm formation.  
Whenever a new prosthesis is implanted into a previously infected site the surgeon must be aware 
of increased risk of failure, both in single or two stage revisions. Eventual removal therefore should 
be easy with low risk of additional damage to the bony substance. On the other hand it should also 
have potential of a good long term result in case of success. Cemented revisions generally show 
inferior long term results compared to uncemented techniques; the addition of antibiotics to 
cement reduces its biomechanical properties. Efficient cementing techniques will result in tight 
bonding with the underlying bone, making eventual removal time consuming and possibly associ-
ated with further damage to the osseous structures. All these issues are likely to make unce-
mented revisions more desirable.  
Allograft bone may be impregnated with high loads of antibiotics using special incubation tech-
niques. The storage capacities and pharmacological kinetics of the resulting antibiotic bone 
compound (ABC) are more advantageous than the ones of antibiotic loaded cement. ABC pro-
vides local concentrations exceeding those of cement by more than a 100fold and efficient release 
is prolonged for several weeks. The same time they are likely to restore bone stock, which usually 
is compromised after removal of an infected endoprosthesis. ABC may be combined with 
uncemented implants for improved long term results and easy removal in case of a failure. Speci-
fications of appropriate designs are outlined. 
Based on these considerations new protocols for one stage exchange of infected TJR have been 
established. Bone voids surrounding the implants may be filled with antibiotic impregnated bone 
graft; uncemented implants may be fixed in original bone. Recent studies indicate an overall success 
rate of more than 90% without any adverse side effects. Incorporation of allografts appears as after 




Antibiotic loaded bone graft seems to provide sufficient local antibiosis for protection against 
colonisation of uncemented implants, the eluted amounts of antibiotics are likely to eliminate 
biofilm remnants, dead space management is more complete and defects may be reconstructed 
efficiently. Uncemented implants provide improved long term results in case of success and fa-
cilitated re-revision in case of failure. One stage revision using ABC together with uncemented 
implants such should be at least comparably save as multiple stage procedures, taking advantage of 
the obvious benefits for patients and economy.  
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Infection of a total hip replacement (THR) is 
considered a devastating complication. Due to the 
absence of well-designed prospective, randomised, 
controlled studies with a sufficient follow-up period, 
diagnosis and treatment of prosthetic joint infections 
is mainly based on tradition, personal experience and 
liability aspects. It is generally accepted, that implants 
and necrotic tissue are covered with bacterial colonies 
that show inherent resistance to both host defence 
mechanisms and antimicrobial chemotherapy making 
the treatment extremely difficult. Uncertainty on the 
most effective approach has lead to several sugges-
tions for treatment. Surgical debridement with im-
plant retention is limited to very selected cases; most 
authors consider thorough removal of all implants 
and necrotic tissue a prerequisite for cure. Most con-
troversies arise about the timing of reinsertion of a 
new prosthesis. In recent years, two-stage exchange 
arthroplasty has been claimed being the gold stan-
dard for treating infection, mostly in combination 
with spacers in the form of antibiotic loaded poly-
methylmethacrylate (PMMA). But there are no evi-
dence based publications, no randomized data and 
only few metaanalyses available on the topic. Many 
protocols base on assumptions making the treatment 
“more art than science”. Several reasons for difficul-
ties in orthopaedic device related infections (ODRI) 
have been elucidated in the last years but that 
knowledge still is not yet fully reflected in therapeutic 
consequences of general practice. Most suggestions 
still are based on the traditional conceptions of an-
timicrobial treatment dealing with freely floating 
bacteria. Planktonic bacteria may well be eliminated 
by conventional use of antibiotics, however, in ODRI 
we have to deal with phenotypically different forms 
of bacteria and our most obstinate opponents are not 
the familiar planktonic pathogens but their sessile 
forms embedded in biofilms 1,2 Addressing the issues 
related to the biofilm concept, a one stage approach 
seems to show results comparable with multiple stage 
revisions 3. 
Bacterial cultures and antibiotic susceptibil-
ity 
The gold standard for detection and classifica-
tion of infection during the last 100 years has been 
bacterial culture. Most protocols for treating infected 
THR base on the microbiological results obtained pe-
rioperatively. However, it has turned out that the tra-
ditional and routinely used methods of culturing are 
likely to detect only a small detail of the whole spec-
trum of pathogens possibly involved in infection of a 
THR 4. It is well known since decades that small col-
ony variants (SCV) of staphylococci and other patho-
gens may survive5 and even replicate6 intracellularily, 
in osteoblasts, endothelial cells and even in poly-
morphonuclear leukocytes and macrophages. Such 
populations are often missed by conventional culture. 
The problem of diagnosis markedly increases taking 
into account the issue of bacterial phenotypes inside 
biofilms. Sonication of explanted devices may dis-
lodge adherent biofilms, culturing the sonication fluid 
is likely to raise sensitivity of cultures significantly. 
Especially in patients having received antimicrobial 
therapy within 14 days before culture the sensitivities 
of periprosthetic tissue and sonicate-fluid culture rise 
from 45.0% to 75.0% 7. Using immunofluorescence 
microscopy for visualizing dislodged pathogens after 
marking with specific antibodies reveals further 3 
times more colonies than seen with light microscopy, 
amplification of bacterial genomes using PCR shows 
bacterial RNA in more than 70% of all THR revision 
cases, including the so called “aseptic” failures 8,9. The 
more sophisticated tools also evidenced, that po-
lymicrobial colonisation is rather the rule than the 
exception after prolonged persistence of infection10. 
All these findings indicate that the incidence and di-
mension of prosthetic joint infection is grossly un-
derestimated by current culture detection meth-
ods11,12.  
Most of the bacteria cultured from orthopaedic 
implants show reduced susceptibility for antibiotics, 
even in their planktonic form 13, whereas there is a 
significant correlation with previous use of gen-
tamicin loaded PMMA14. Most pathogens not identi-




against antibiotics 15. SCVs require up to 100 fold an-
tibiotic concentrations for elimination, but usually are 
accessible by systemic antibiosis, as long as the chosen 
antibiotics show intracellular activity and application 
lasts long enough16,17. Biofilm embedded pathogens 
require up to 1000 fold concentrations for elimina-
tion18 and such usually are inaccessible for systemic 
antibiotic therapy as well as for antibiotics released 
from PMMA 19,20. 
Debridement 
Radical debridement is prerequisite for cure in 
any orthopaedic infection but an infected operative 
site cannot be sterilized by debridement alone. De-
bridement shall remove the predominant amount of 
bioburden but even the most careful cleaning cannot 
prevent residual small bacterial colonies being dis-
placed to new habitats in niches of the debrided site. 
Antibiotic concentrations reached by systemic anti-
biosis or local therapy with commercially available 
antibiotic carriers may provide eradication of plank-
tonic residues but are not effective in eliminating mi-
cro-clusters disrupted from biofilms that may be the 
cause of recurrence after an indefinite period of time. 
Fragments of biofilms seem to be more vulnerable for 
antibiotics compared with intact biofilm systems 21,22 
but their elimination still requires concentrations ex-
ceeding the ones provided by systemic or conven-
tional local antibiotic therapy. For eliminating resid-
ual biofilm fragments a novel approach is necessary, 
providing sufficiently high local antibiotic concentra-
tions for a prolonged period of time 23.  
Dead space management and reconstruction 
After removal of infected endoprostheses and 
radical necrosectomy bony defects always will be 
present. Filling of dead space has been considered 
mandatory since the old days of septic surgery24. It 
may be presumed that whatever filler is used it needs 
some kind of protection against colonisation with 
remaining bacteria. Dead space management after 
infected THR may be performed with antibiotic 
loaded cement, spacers or bead chains. It should be 
kept in mind, that those devices beside their me-
chanical function cannot be considered as an antim-
icrobial tool; their antibiotic content provides short 
lived prophylactic aid against planktonic bacteria but 
is not capable of sterilizing sites contaminated with 
sessile bacteria and provide no protection against 
biofilm colonisation 25-28. Reconstruction of defects 
seems to be favourable with regard to possible further 
revisions. Allograft bone is widely used for recon-
struction of bony defects and performs favourably in 
two stage revisions of THR 29. However, unvascular-
ized bone grafts are at risk to become contaminated 
and need protection as well. When loading bone 
grafts with antibiotics it turned out, that their storage 
capability for antibiotics exceeds those of PMMA by 
far  30-32. Especially when using highly purified can-
cellous bone as a carrier local concentrations of up to 
20.000mg/l can be released with Vancomycin and up 
to 13.000mg/l with Tobramycin 33. With this kind of 
impregnation the whole amount of loaded antibiotic 
is available for antimicrobial activity and the activity 
remains far beyond the susceptibility of relevant 
pathogens for several weeks. These capacities make 
them more attractive for local therapy and allow us-
ing uncemented implants. If cortical bone should be-
come preferable out of whatever circumstances it can 
be loaded with antibiotics as well34. Using adequate 
impregnation technique antibiotics may elute simi-
larly effective as is the case with cancellous bone 33. 
Kinetics are different but still capable of eliminating 
surrounding pathogens.   
Antibiotic delivery 
Since concentrations provided by systemic anti-
biotic therapy and commonly available carrier sys-
tems are insufficient in eliminating biofilm bacteria 
new ways of antibiotic delivery are required. The cri-
teria of antibiotics for efficacy against biofilms are 
different from those meant for action against plank-
tonic bacteria. In any case the high concentrations 
needed are only feasible by local application. Failure 
of antibiotics to cure prosthesis-related infection is not 
only due to poor penetration of drugs into biofilm but 
likely due to delayed antimicrobial effect on station-
ary bacteria in the biofilm environment. In evaluating 
novel systems the used antibiotics must pass several 
tests qualifying them for that purpose. Few antibiotics 
have been identified to meet those criteria, among 
them Vancomycin seems to be the most widely 
evaluated one. Vancomycin is one of the antibiotics 
with intracellular bactericidal activity and therefore 
should cover SCVs of staphylococci 35. It is likely to 
penetrate glycocalices very rapidly 36-38. Once incor-
porated in biofilm Vancomycin shows a strain de-
pendent bactericidal biofilm activity between 8 times 
39 and 128 times 40 the MIC of planktonic bacteria. 
Vancomycin shows superior bactericidal activity 
against biofilm embedded staphylococci and espe-
cially MRSA 41 compared with most other antibiotics. 
Keeping local vamcomycin concentration at levels 
around 32x the MIC of planktonic forms the station-
ary phase pathogens are reduced by 2 logs within 24h 
42. Vancomycin shows the least cytotoxic effect of all 
commonly used antibiotics 43 and is not likely to cause 




comycin shows very poor tissue penetration45,46, 
which has been considered a disadvantage in intra-
venous application47,48; however the disadvantage 
turns into an advantage in local application since vice 
versa there is also reduced penetration from the im-
planted site into the vascular system, keeping local 
tissue levels high and systemic levels low . It therefore 
may be suggested that local application of antibiotics 
with similar properties as Vancomycin together with 
an appropriate carrier may be a valuable tool against 
ODRI. The carrier should provide for high initial lev-
els to penetrate remaining glycocalices rapidly and 
consequently shall keep the concentrations above the 
critical level (which in the case of Vancomycin may be 
estimated to be between 200 and 500 mg/l) for a 
minimum of 72 hours. 
To address the problem of potentially unde-
tected polymicrobial colonisation it seems favourable 
to reserve monotherapy to cases with strong evidence 
of monomicrobial grampositive infection, i.e. acute 
onset of symptoms with typical clinical appearance 
(fever, pus) and unambiguous culture. Chronic infec-
tions the same as cases with prior infection related 
surgery or inexplicit cultures should be treated with a 
combination of two or more antibiotics, whereas 
combinations of vancomycin with tobramycin seem to 
be favourable, taking advantage of the synergistic 
activity of the two antibiotics 49,50. This combined ap-
proach should be likely to cover most of the relevant 
pathogens since resistance to both antibiotics at the 
same time is found extremely rarely. 
Choice of Implants 
Whenever a new prosthesis is implanted into a 
recently infected site the surgeon must be aware of 
increased risk of failure, both in single or two stage 
revisions. Eventual removal therefore should be easy 
with low risk of additional damage to the bony sub-
stance in such a case. On the other hand it should also 
have potential of a good long term result in case of 
success. This limits the choice of advisable implants. 
Cemented systems seem to be less likely for that 
purpose since efficient cementing techniques will re-
sult in strong bonding with the underlying bone. 
Eventual removal such will be time consuming and 
possibly associated with further damage to the osse-
ous structures51. Cemented revisions generally show 
inferior long term results compared to uncemented 
techniques 52,53; the addition of antibiotics further re-
duces the biomechanical properties of cement 54-56. 
Bone cement (PMMA) has been shown to be the ideal 
substrate for bacterial attachment and replication of 
sessile bacterial phenotypes40. Addition of antibiotics 
may be likely to act as a prophylactic aid against low 
bacterial numbers during the first days after implan-
tation but cannot avoid colonization with high in-
ocula57, prevent biofilm formation on its surface 20,58 or 
even eliminate established biofilms59. On the 
acetabular side uncemented hemispherical cups are 
well suited since stability mainly can be supplied by 
good contact at the rim or additional screw fixation, 
while the bottom may be filled with cancellous bone 
graft. The mode of fixation makes it also easy to re-
move it again without compromising the natural 
bone. The use of uncemented hemispherical cups with 
or without screws in supplying acetabular defects is 
well established 60-62 and meanwhile proven to be su-
perior compared with cemented systems 52,62. On the 
femoral side a stem with rectangular diameter may 
offer several advantages: fixation relies mainly on 
contact of its medial and lateral edges with original 
bone while the anterior and posterior aspect may be 
covered with antibiotic impregnated bone graft. Sta-
bility of that design has been shown to be reliable as 
long as its distal third is safely anchored in healthy 
own bone while eventual removal usually is achiev-
able without major difficulties 3. The most common 
defects up to Paprosky type 3 such can be supplied 
favourably 63,64. Other uncemented designs may pro-
vide comparable results as long as a safe distal fixa-
tion can be obtained 65-67. In the case of a large type 4 
defect longer sized types may become necessary, 
whereas modular systems seem to be favourable. 
One stage –two stage   
It is undoubted that one stage protocols, if suc-
cessful, provide the best benefit both for the patient 
and the society. Still the fear of reinfection dominates 
the surgeons’ decisions and directs them to multiple 
stage protocols. However, there is no scientifically 
based argument for that practice. Successful eradica-
tion of infection with two stage procedures is reported 
to average 80% to 98%,68,69 whereas there are no sig-
nificant differences between revisions with 70or 
without71 antibiotic loaded cement, with short or long 
term antibiotic therapy, with or without the use of 
spacers and other differences. On the other hand a 
literature review of Jackson and Schmalzried72 sum-
marizing the results of 1,299 infected hip replace-
ments treated with direct exchange (almost exclu-
sively using antibiotic loaded cement), reports of 1,077 
(8 3% )  h av in g  b een  s uc c es sfu l.  I t  m ay  b e c a lc u l at ed , 
that adding a second one stage procedure for treating 
the failed cases the overall result with two operations 
may improve to >95%, an outcome which is at least as 
good as the best results after two stage revisions, 
while requiring two surgical interventions for only a 




been proven to be useful for improving final func-
tional results; however, concerning infection control 
no benefit could be shown. These results suggest, that 
the major factor for a successful outcome with tradi-
tional approaches may be found in the quality of the 
surgical debridement and dead space management 71. 
Dead space management is performed by a new 
prosthesis the same as with a spacer with the addi-
tional advantage of a definitive prosthesis providing 
stability, which a spacer does not. As long as protec-
tion against colonization is granted by high local an-
tibiotic concentrations a well fixed prostheses is likely 
to provide better results than a spacer. Failures in all 
protocols seem to be caused by small fragments of 
bacterial micro-colonies remaining after debridement, 
whereas neither systemic antibiotics nor antibiotic 
loaded PMMA seem to be able to eliminate them. An-
tibiotic loaded bone graft seems to provide efficient 
antibiosis with respect to ODRI. Implants may suffi-
ciently be protected against colonisation, the eluted 
amounts of antibiotics are likely to eliminate biofilm 
remnants, dead space management is more complete 
and as a positive side effect defects may be recon-
structed efficiently. One stage revision using unce-
mented implants and antibiotic impregnated bone 
graft such should be comparably save as multiple 
stage procedures, taking advantage of the obvious 
benefits for patients and economy. 
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